Profound Medical Corp

As of June 30, 2026, Profound Medical Corp carries a market capitalization of 344.50M, placing it among publicly traded companies globally. Its enterprise value stands at 300.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Profound Medical Corp's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Profound Medical Corp has 36.53M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 11.62, and the price-to-book ratio stands at 4.87.

These figures are as of June 30, 2026. The EV/Sales ratio of 11.10 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 300.66M versus a market cap of 344.50M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Profound Medical Corp maintains a current ratio of 6.46, meaning it holds 6.5x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Profound Medical Corp posted a negative return on equity (ROE) of -73.53, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -58.45, reflecting losses generated across the asset base. The company generates approximately 172,528.93 in revenue per employee across its workforce of 157.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.57 indicates how many times Profound Medical Corp sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Profound Medical Corp recorded 322,160.67 in income tax expense. The company reported a pretax loss of -46.15M and -46.47M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Profound Medical Corp's stock has gained approximately 5.90% over the past 52 weeks. The 50-day moving average sits at 8.88, while the 200-day moving average is 9.37.

Over the twelve months ended June 30, 2026, Profound Medical Corp generated 27.09M in revenue and converted that into -46.47M in net income, yielding earnings per share of -1.39. EBITDA reached -49.50M, while operating income came in at -50.20M.

As of June 30, 2026, Profound Medical Corp holds 54.31M in cash and equivalents against 10.47M in total debt, resulting in a net debt position of -47.92M. Total book value stands at 70.69M, with working capital of 70.61M providing operational flexibility.

Profound Medical Corp produced -51.23M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Profound Medical Corp posted a gross margin of 71.79, reflecting its pricing power and cost economics. The operating margin of -185.31 and net profit margin of -171.57 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -16.28: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -17.07, meaning Profound Medical Corp raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Profound Medical Corp's most recent stock split took place on October 16, 2019 with a 10:1 split ratio.

As of June 30, 2026, Profound Medical Corp has an Altman Z-Score of 4.13, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.